Aravax secures $4.85 million in venture funding - MarketLine Financial Deals

Aravax secures $4.85 million in venture funding

Aravax secures $4.85 million in venture funding - MarketLine Financial Deals
Aravax secures $4.85 million in venture funding
Published Nov 23, 2015
2 pages — Published Nov 23, 2015
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Aravax, an Australia-based developer of a vaccine for peanut allergies, has secured $4.85 million in venture capital funding.

  
Source:
Document ID
MA162265_151127
Country
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Aravax secures $4.85 million in venture funding" Nov 23, 2015. Alacra Store. Dec 05, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Aravax-secures-4-85-million-in-venture-funding-2052-115756>
  
APA:
MarketLine Financial Deals. (2015). Aravax secures $4.85 million in venture funding Nov 23, 2015. New York, NY: Alacra Store. Retrieved Dec 05, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Aravax-secures-4-85-million-in-venture-funding-2052-115756>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.